Global Ganja Report

It was federal subsidies for healthcare that were center-stage in the government shutdown and the Capitol Hill deal that finally ended it. But the fight over the heretofore ambiguous legal status of hemp-derived THC was also at issue in the end—and this could represent a serious blow to America’s farmers.

In the ultimate imprimatur of mainstream acceptance, the 10th annual Cannabis World Congress & Business Expo was held June 5-6 in Manhattan’s Javits Convention Center, the Big Apple’s premier venue for trade shows and industry confabs. And the event had the open participation of New York city and state government agencies, as well as capitalist enterprises from around the country and the planet.

In a paradox, New York authorities are finally unleashing the long-anticipated crackdown on the state’s legion and proliferating unlicensed cannabis retailers—while the licensing program continues to be slowed by obstacles, including legal challenges.

Small producers have long been wary of the cannabis industry coming under domination by multi-state operators with the worst practices of corporate America. But the revelations of Russian oligarch money in the coffers of leading MSO Curaleaf appear to vindicate even the most cynical observers. These follow a slew of controversies concerning product safety and labor rights at the company.

The arrival of a major US multi-state operator in Bangkok is a sign of the global cannabis industry's big ambitions for Thailand, the first Asian country to decriminalize. But with enabling legislation still pending, the regulatory environment remains uncertain.

The legalization of hemp-derived cannabinoids by the 2018 Farm Bill has left a yawning regulatory gap that is being avidly exploited by purveyors of high-potency edibles and sketchy vape products.


That's the contention of a report just issued by the leading California cannabis trade group, warning that the law inadvertently opened a "Pandora's box" that poses threats to public health.

The cannabis industry is globalizing fast, which means changes for mainstays of commercial production in Europe and North America, and new players coming on line from regions such as the Middle East, Southeast Asia and Central America. Here’s a brief overview of a few entries from these categories.

With political and legal space opening for cannabis in state after state, a backlash is manifesting in the idea of caps on the potency—whether of bud, extracts or edibles. Voices from the industry and activist community see this as a throwback to the days of Reefer Madness.